Navigation Links
Abbott's Humira(r) (Adalimumab) Gets Approval by EU for Crohn's Disease Treatment

ABBOTT PARK, Ill., Abbott announced today that it has received marketing authorization from the European Commission for the use of HUMIRA(R) (adalimumab) as a treatment for severe Crohn's disease. HUMIRA is the first self-administered biologic for the treatment of Crohn's disease and offers an effective and convenient treatment option that can help enable patients to maintain control of their disease. This announcement follows FDA approval for the Crohn's disease indication, which Abbott received in February, and is the fourth approved indication for HUMIRA in the United States and the European Union.

Crohn's disease is a serious, chronic, inflammatory disease of the gastrointestinal (GI) tract that affects more than 1 million people in North America and Europe. It affects people of all ages, but it is primarily a disease of young adults, with onset typically before age 40. There is no medical or surgical cure for Crohn's disease and few treatment options exist for patients suffering with this chronic condition.

"Crohn's can have a devastating impact on patients, many of whom are young and active, making it difficult to carry out normal day-to-day activities," said Rod Mitchell, chairman, European Federation of Crohn's & Ulcerative Colitis Associations. "The unpredictable nature of the disease can seriously impact their quality of life and self-esteem. For the half million people across Europe suffering from Crohn's, this approval offers hope to help them regain control of their disease."

Common symptoms of Crohn's disease include diarrhea, cramping, abdominal pain, weight loss, fever, and in some cases, rectal bleeding. Complications include intestinal obstruction, fistulas (ulcers that form tunnels to surrounding tissues), and malnutrition. Over the course of their disease, as many as 75 percent of patients with Crohn's disease will undergo surgery at least once for complications or disease resistant to treatment. Of thos e who undergo surgery to remove a portion of the intestines (resection), half will experience a relapse within five years.

"After I was diagnosed with Crohn's, the unpredictable symptoms made working and relationships difficult. I was afraid to leave the house," said Rocio Lopez, a HUMIRA clinical trial patient. "With HUMIRA, my Crohn's symptoms are under control and I have more freedom to live my life."

"The approval of HUMIRA in Crohn's disease means that an underserved patient population now has a clinically effective treatment option that they can administer themselves," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development at Abbott. "For the thousands of people across Europe with Crohn's disease, HUMIRA represents a new, effective, and convenient treatment option."


'"/>




Related medicine news :

1. Approval for DNA test to detect cystic fibrosis
2. Vaccine For Cervical Cancer Awaits Approval
3. WHO Gives Its Approval For Bird Flu Test Kit
4. FDA Gives Its Approval For Inhaler
5. RotaTeq Gets US Approval
6. Better Communication With FDA Could Speed Up Approval Of New Drugs
7. Nerve Stimulator for Depression Though Not Effective Was Given Approval
8. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
9. Global Education Net Pvt Medical College Gets MCI Approval
10. Approval of Drugs for the Treatment of Late-Stage Cancer
11. Lupin Gets USFDA Approval For Quinapril Tablets
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... ... ... Quorum Health announced that Robert A. Vento has been appointed as president ... promoted to COO of QHR. , A national search was launched for ... in December 2016. , “I’m pleased to announce these leadership promotions ...
(Date:6/28/2017)... ... 2017 , ... Continually at the forefront of sweetener innovation, ... received the Non-GMO Project Verified seal. All five flavors of the plant-based, sugar-free ... verification for non-GMO foods and products in North America. , Available in Caramel, ...
(Date:6/28/2017)... , ... June 28, 2017 , ... Guide to FDA ... , No matter on which side of the Atlantic devicemakers do business, this ... they have to follow. , In addition to the full text of the FDA’s ...
(Date:6/28/2017)... ... June 28, 2017 , ... Anyone with a remote control has seen the never-ending twists on ... the flipper will get rich in no time. But what about the buyers of ... for the buyer of a flipped house. An email recently sent to Gary Case ...
(Date:6/28/2017)... ... June 28, 2017 , ... David B. Sosin, a founding partner at the ... the post of 2nd Vice President for the Illinois State Bar Association , in ... ISBA’s 3rd Vice President in 2016 following a state-wide election and served in that capacity ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... LOS ANGELES , June 8, 2017   Responding ... prescription drug oversight and the death of singer Chris ... Commission on Human Rights International offers a free online ...  to better educate consumers and families about psychotropic drug risks. ... Heath Ledger , who died from an accidental overdose, has ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ) today ... R. Goodwin , U.S. District Court Judge for the ... entered a case management order in MDL 2325, American ... (the "MDL") that includes a provision requiring plaintiffs in ... specific causation within one hundred twenty (120) days of ...
(Date:6/7/2017)... -- Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. (NYSE: ... Iowa location. The Iowa ... ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition formulations. ... pollutants. "Our new cleanroom will ... our Iowa patients," said Phil Rielly ...
Breaking Medicine Technology: